PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21040761-11	2011	However, when cells were pretreated with inhibitors (5-aza-CdR or U0126), the effects of arsenite on Cyclin-D1 and p16 expression were suppressed.	U 0126	66-71	cyclin D1	Homo sapiens	101-110	
22811014-9	2012	The intracisternal administration of U0126 (an MEK inhibitor), previous to the excitotoxic lesion, decreased the activation of ERK1/2 and the expression of cyclin D1 and cyclin B in the hippocampus.	U 0126	37-42	cyclin D1	Homo sapiens	156-165	
22678010-11	2012	Cyclin D1 mRNA and protein concentrations in serum-stimulated podocytes were reduced after blocking ERK activation by U0126.	U 0126	118-123	cyclin D1	Homo sapiens	0-9	
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	cyclin D1	Homo sapiens	139-148	
19996316-5	2010	Specifically, we identified the extracellular signal-regulated kinase (ERK) signaling pathway as a mediator of signals from FcgammaR activation to cyclin D1 expression, because cyclin D1 expression associated with FcgammaR cross-linking was attenuated by specific inhibitors of the ERK1/2 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.	U 0126	320-325	cyclin D1	Homo sapiens	177-186	
19996316-5	2010	Specifically, we identified the extracellular signal-regulated kinase (ERK) signaling pathway as a mediator of signals from FcgammaR activation to cyclin D1 expression, because cyclin D1 expression associated with FcgammaR cross-linking was attenuated by specific inhibitors of the ERK1/2 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.	U 0126	320-325	cyclin D1	Homo sapiens	147-156	
18573488-8	2008	Furthermore, fluoxetine-induced activation of both the cAMP-response element-binding (CREB) protein and extracellular signal-regulated protein kinases (ERK1/2), which was abolished by the selective inhibitor of MAP kinase kinase (MEK) 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), and increased cyclin D1 expression.	U 0126	235-294	cyclin D1	Homo sapiens	318-327	
19763792-9	2010	Finally, blockade of either CaM KK (with STO-609) or ERK (with U0126) activities resulted in the inhibition of carbachol- and estrogen-mediated cyclin D1 expression and MCF-7 cell growth.	U 0126	63-68	cyclin D1	Homo sapiens	144-153	
19589865-6	2009	The MAPK kinase-1/2 inhibitor, U0126, fully restored cAMP down-regulation of CCND1, but not cAMP up-regulation of IGFBP1, in hESF of women with vs. without endometriosis.	U 0126	31-36	cyclin D1	Homo sapiens	77-82	
18852162-2	2009	The E(2)-induced proliferation was associated with the activation of extracellular signal-regulated kinase (MAPK)3/1 and up-regulation of cyclin D1 and E, which were suppressed by the addition of an MAP2K inhibitor (U0126) or an ER antagonist (ICI 182 780).	U 0126	216-221	cyclin D1	Homo sapiens	138-153	
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P > 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P < 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P < 0.05], as compared with those of the PMA treated group.	U 0126	11-16	cyclin D1	Homo sapiens	197-205	
15547725-8	2004	Treatment of HepG2 cells with MEK1/2 inhibitor U0126 resulted in cell cycle arrest, downregulation of cyclin D1 and Cdk-2 expression and inhibition of pRB phosphorylation at Ser780 and Ser795.	U 0126	47-52	cyclin D1	Homo sapiens	102-111	
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	cyclin D1	Homo sapiens	221-230	
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	cyclin D1	Homo sapiens	75-84	
11267961-11	2001	In addition, U0126, which is a potent inhibitor for ERK phosphorylation, antagonized increase of cyclin D1, thus suggesting that EGF- or HGF-mediated ERK phosphorylation might have played an essential role for cell growth.	U 0126	13-18	cyclin D1	Homo sapiens	97-106	
11123423-5	2000	EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF.	U 0126	66-71	cyclin D1	Homo sapiens	145-154	
31986415-13	2020	MIF-induced increase in cyclin D1 mRNA level also was inhibited only by U0126 following MIF stimulation.	U 0126	72-77	cyclin D1	Homo sapiens	24-33	
14576498-13	2003	The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment.	U 0126	130-135	cyclin D1	Homo sapiens	48-57	
11290527-5	2001	In addition, U-0126 inhibited mitogen-induced activation of p90 ribosomal S6 kinase and expression of c-Fos and cyclin D1, all of which are downstream from ERK in the signaling cascade that leads to cell proliferation.	U 0126	13-19	cyclin D1	Homo sapiens	112-121	
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	cyclin D1	Homo sapiens	86-91	
29528074-7	2018	Treatment with U0126 also significantly decreased Cyclin D1 protein expression while JNK and p38 inhibitors did not attenuate the arsenite-associated increase in Cyclin D1 protein expression.	U 0126	15-20	cyclin D1	Homo sapiens	50-59	
23852369-4	2013	Here we show that in p21- and p16-induced senescence, inhibitors of mitogen-activated/extracellular signal-regulated kinase (MEK) (U0126, PD184352 and siRNA) completely prevented cyclin D1 accumulation, making it undetectable.	U 0126	131-136	cyclin D1	Homo sapiens	179-188	
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	U 0126	83-88	cyclin D1	Homo sapiens	30-39	
25174327-8	2014	Erk1/2 inhibition with either U0126 treatment or specific siRNA silencing resulted in decreases in p-ser STAT3 and cyclin D1 levels and increases in p-tyr STAT3 in OSCC cells.	U 0126	30-35	cyclin D1	Homo sapiens	115-124	
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	cyclin D1	Homo sapiens	118-126	
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	cyclin D1	Homo sapiens	208-216	
25017118-8	2014	Pretreatment with the ERK1/2-specific inhibitor U0126 and pertussis toxin prevented the suppression of cyclin D1 expression, however did not affect DNA ladder formation.	U 0126	48-53	cyclin D1	Homo sapiens	103-112	
23852369-6	2013	In such cells, U0126 by itself induced senescence that was remarkably cyclin D1 negative.	U 0126	15-20	cyclin D1	Homo sapiens	70-79	
23852369-9	2013	We confirmed that the inhibitor of CDK4/6 caused cyclin D1 positive senescence in normal RPE cells, whereas U0126 prevented cyclin D1 expression.	U 0126	108-113	cyclin D1	Homo sapiens	124-133